Skip to main content
Premium Trial:

Request an Annual Quote

IncellDx Gains ISO Certification

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Silicon Valley molecular diagnostics firm IncellDx today said that it has achieved ISO 13485:2003 and ISO 9001:2008 certification.

Both certifications came with no deficiencies, the company said.

Based in Menlo Park, Calif., IncellDx's lead technology, called simultaneous ultrasensitive subpopulation staining/hybridization in situ, or SUSHI, is a method for getting the company's reagents into a cell in order to amplify signals. In January, the company announced it had raised $3 million in a Series A financing round to fund a clinical trial for its human papillomavirus test.

IncellDx today said that it will run clinical trials on the test this year followed by an application for FDA clearance.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.